{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "## Import Library\n",
    "\n",
    "import openai\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import AzureDeveloperCliCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.indexes import SearchIndexClient\n",
    "from azure.search.documents.indexes.models import (\n",
    "    HnswParameters,\n",
    "    PrioritizedFields,\n",
    "    SearchableField,\n",
    "    SearchField,\n",
    "    SearchFieldDataType,\n",
    "    SearchIndex,\n",
    "    SemanticConfiguration,\n",
    "    SemanticField,\n",
    "    SemanticSettings,\n",
    "    SimpleField,\n",
    "    VectorSearch,\n",
    "    VectorSearchAlgorithmConfiguration,\n",
    ")\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "import openai\n",
    "import os\n",
    "from langchain.embeddings.openai import OpenAIEmbeddings\n",
    "from langchain.vectorstores.azuresearch import AzureSearch\n",
    "\n",
    "from azure.storage.blob import BlobServiceClient\n",
    "from azure.core.exceptions import ResourceExistsError\n",
    "import json\n",
    "\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "#from langchain.retrievers import AzureCognitiveSearchRetriever\n",
    "from langdetect import detect\n",
    "from langchain.prompts import PromptTemplate\n",
    "import re\n",
    "# Create chain to answer questions\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.chains.question_answering import load_qa_chain\n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chains import LLMChain\n",
    "\n",
    "# Import Azure OpenAI\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.schema import HumanMessage\n",
    "\n",
    "#import textwrap\n",
    "import logging\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "\"\"\"#setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"gptdemosearch\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"PcAZcXbX2hJsxMYExc2SnkMFO0D94p7Zw3Qzeu5WjYAzSeDMuR5O\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"sino-hr-chatbot\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\"\"\"\n",
    "\n",
    "# setting up credentials\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"] = \"acs-testing-sunny\" # replace with yours search service name\n",
    "os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"] = \"oygYftyrBXiWoDLoZatDKNSLFttn9frM6DE4XlSb7kAzSeBR01eY\" # replace with your api key\n",
    "os.environ[\"AZURE_INDEX_NAME\"] = \"your-index-name\" #\"namfung-finance-chatbot\" # \n",
    "# end setting up credentials\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 5 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the page where your answer is based on \n",
    "    5. Please provide the page number in the following output format: [Page: 1]\n",
    "    \n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    \n",
    "    文本：{context}\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def initialize_vector_store():\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "    \n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "    \n",
    "    return vector_store"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def azure_search_by_index(question, index_name):\n",
    "\n",
    "    # set up openai environment\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    search_service = os.environ[\"AZURE_COGNITIVE_SEARCH_SERVICE_NAME\"]\n",
    "    search_api_key = os.environ[\"AZURE_COGNITIVE_SEARCH_API_KEY\"]\n",
    "    vector_store_address: str = f\"https://{search_service}.search.windows.net\"\n",
    "    vector_store_password: str = search_api_key\n",
    "    \n",
    "\n",
    "    # define embedding model for calculating the embeddings\n",
    "    model: str = \"text-embedding-ada-002\"\n",
    "    embeddings: OpenAIEmbeddings = OpenAIEmbeddings(deployment=model, chunk_size=1)\n",
    "    embedding_function = embeddings.embed_query\n",
    "\n",
    "    # define schema of the json file stored on the index\n",
    "    fields = [\n",
    "            SimpleField(\n",
    "                name=\"id\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                key=True,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"content\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            SearchField(\n",
    "                name=\"content_vector\",\n",
    "                type=SearchFieldDataType.Collection(SearchFieldDataType.Single),\n",
    "                searchable=True,\n",
    "                vector_search_dimensions=len(embedding_function(\"Text\")),\n",
    "                vector_search_configuration=\"default\",\n",
    "            ),\n",
    "            SearchableField(\n",
    "                name=\"metadata\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field to store the title\n",
    "            SearchableField(\n",
    "                name=\"title\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                searchable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"source\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"page\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "            # Additional field for filtering on document source\n",
    "            SimpleField(\n",
    "                name=\"website_url\",\n",
    "                type=SearchFieldDataType.String,\n",
    "                filterable=True,\n",
    "            ),\n",
    "        ]    \n",
    "    \n",
    "    vector_store: AzureSearch = AzureSearch(\n",
    "        azure_search_endpoint=vector_store_address,\n",
    "        azure_search_key=vector_store_password,\n",
    "        index_name=index_name,\n",
    "        embedding_function=embedding_function,\n",
    "        fields=fields,\n",
    "    )\n",
    "\n",
    "    relevant_documentation = vector_store.similarity_search(query=question, k=1, search_type=\"similarity\")\n",
    "    \n",
    "    context = \"\\n\".join([doc.page_content for doc in relevant_documentation])[:10000]\n",
    "\n",
    "    lang = detect(context)\n",
    "\n",
    "    #print(doc)\n",
    "    #print(context)\n",
    "    #print(relevant_documentation)\n",
    "    source = relevant_documentation[0].metadata['source']\n",
    "    #page_no = relevant_documentation[0].metadata['page']\n",
    "    website_url = relevant_documentation[0].metadata['website_url']\n",
    "    \n",
    "    page_no = \"\"\n",
    "    for doc in relevant_documentation:\n",
    "        page_no = page_no + \",\" + doc.metadata['page'] \n",
    "    \n",
    "    #print(relevant_documentation[0])\n",
    "    #print(source)\n",
    "    #print(page_no)\n",
    "    #print(website_url)\n",
    "    #return str(context), source, website_url, lang, page_no\n",
    "    # just return 10 documents (i.e. pages) if number of pages return from the search result > 10\n",
    "    if len(relevant_documentation) > 10:\n",
    "        relevant_documentation = relevant_documentation[0:9]\n",
    "    else:\n",
    "        relevant_documentation = relevant_documentation\n",
    "    return relevant_documentation, source, website_url, lang, page_no\n",
    "\n",
    "\n",
    "# helper function to extract page number\n",
    "def extract_page_no(string):\n",
    "    if \"[Page\" in string:\n",
    "        print(re.findall('\\[Page:.*\\]', string)[0].split('Page:')[1])\n",
    "        return re.findall('\\[Page:.*\\]', string)[0].split(':')[1].split(\"]\")[0].strip()\n",
    "    else:\n",
    "        return \"/\"\n",
    "\n",
    "def extract_answer(string):\n",
    "    if \"[Page\" in string:\n",
    "        return string.split(\"[Page\")[0]\n",
    "    else:\n",
    "        return string\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import LLMChain\n",
    "from langchain.llms import AzureOpenAI \n",
    "from langchain.memory import ConversationBufferMemory\n",
    "from langchain.prompts import PromptTemplate\n",
    "from langchain.chat_models import AzureChatOpenAI\n",
    "from langchain.memory import CosmosDBChatMessageHistory\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# do not run, not use this for memory\n",
    "\n",
    "def llm_pipeline(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    #print(relevant_docs)\n",
    "\n",
    "    # generate prompt without example\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        PROMPT = generate_prompt()\n",
    "    else:\n",
    "        PROMPT = generate_prompt_chi()\n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\n",
    "    sessionId = \"101\"\n",
    "    user_id = \"Sunny\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    chain = LLMChain(llm=llm, \n",
    "                    prompt=PROMPT,\n",
    "                    memory=memory\n",
    "                   #verbose=True\n",
    "                    )\n",
    "\n",
    "    output = chain.run({\"context\": relevant_docs, #\"context\": relevant_docs, \n",
    "        \"question\": question,\n",
    "        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def generate_prompt_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    Follow exactly these 5 steps:\n",
    "    1. Read the context below and aggregrate this data\n",
    "    Context : {context}\n",
    "    2. Answer the question using only this context and the chat history below\n",
    "    3. Answer the question in less than 200 words\n",
    "    4. Please provide the page number of the pages where your answer are based on at the end of your response\n",
    "    5. Please provide the page numbers in the following output format: [Page: 1, 2, 3]\n",
    "    \n",
    "    Chat History: {chat_history}\n",
    "\n",
    "    User Question: {question}\n",
    "\n",
    "\n",
    "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n",
    "\n",
    "def generate_prompt_chi_with_history():\n",
    "    prompt_template_string=\"\"\"\n",
    "    指令：\n",
    "    1. 你必须只根据以下文本的内容及谈话记录回答提问者的询问。\n",
    "    2. 如果不懂得回答或文本没有资料，请回答“对不起，我不懂得回答这个问题。”\n",
    "    3. 请以少於200字回答问题。\n",
    "    4. 请在你的回答后提供你用以回答的文本的页数。格式示例：[Page: 1]\n",
    "    \n",
    "    文本：{context}\n",
    "\n",
    "    谈话记录：{chat_history}\n",
    "\n",
    "    #####\n",
    "\n",
    "    问题：{question}\n",
    "\n",
    "    \"\"\"\n",
    "    prompt_template = PromptTemplate(template = prompt_template_string, input_variables=[\"context\", \"question\", \"chat_history\"])\n",
    "\n",
    "    return prompt_template\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chains import ConversationalRetrievalChain\n",
    "\n",
    "def llm_pipeline_with_history(question):\n",
    "    # set up index name \n",
    "    index_name = os.environ[\"AZURE_INDEX_NAME\"] \n",
    "\n",
    "    os.environ[\"OPENAI_API_TYPE\"] = \"azure\"\n",
    "    os.environ[\"OPENAI_API_VERSION\"] = \"2023-05-15\"\n",
    "    os.environ[\"OPENAI_API_BASE\"] = \"https://pwcjay.openai.azure.com/\"\n",
    "    os.environ[\"OPENAI_API_KEY\"] = \"f282a661571f45a0bdfdcd295ac808e7\"\n",
    "\n",
    "\n",
    "    # retrieve information from Azure Search\n",
    "    relevant_docs, source, website_url, language, page_no = azure_search_by_index(question, index_name)\n",
    "\n",
    "    language = detect(question)\n",
    "\n",
    "    if language == \"en\":\n",
    "    #english prompt\n",
    "        QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "    else:\n",
    "        QA_CHAIN_PROMPT = generate_prompt_chi_with_history()\n",
    "\n",
    "    # use AzureChatOpenAI \n",
    "    llm = AzureChatOpenAI(deployment_name=\"gpt-35-16k\", temperature=0,\n",
    "                        openai_api_version=\"2023-05-15\", openai_api_base=\"https://pwcjay.openai.azure.com/\")\n",
    "\n",
    "\n",
    "    # set up chat history database credentials\n",
    "    os.environ[\"COSMOS_ENDPOINT\"] = \"https://gpt-demo-chat-history.documents.azure.com:443/\"\n",
    "    os.environ[\"COSMOS_KEY\"] = \"AZEhMpW4YD3t7iEMgp9at48S7f5ZjvnahUqJMYjMjMpH2QH2wiYBL97RdX7AqL3CMQcGGhbdAFHvACDbDDwMyA==\"\n",
    "    ENDPOINT = os.environ[\"COSMOS_ENDPOINT\"]\n",
    "    KEY = os.environ[\"COSMOS_KEY\"]\n",
    "    DATABASE_NAME = \"sino_demo\"\n",
    "    CONTAINER_NAME = \"sino_chat_history\"\n",
    "\n",
    "    # session id, to be provided by frontend\n",
    "    sessionId = \"103\"\n",
    "    user_id = \"Sunnytesting\"\n",
    "\n",
    "    history = CosmosDBChatMessageHistory(\n",
    "        cosmos_endpoint = ENDPOINT,\n",
    "        cosmos_database = DATABASE_NAME,\n",
    "        cosmos_container = CONTAINER_NAME,\n",
    "        credential = KEY,\n",
    "        session_id = sessionId,\n",
    "        user_id = user_id,\n",
    "    )\n",
    "\n",
    "    history.prepare_cosmos()\n",
    "\n",
    "    vector_store =initialize_vector_store()\n",
    "\n",
    "    retriever = vector_store.as_retriever()\n",
    "\n",
    "    # add chat memory\n",
    "    memory = ConversationBufferMemory(\n",
    "        llm = llm,\n",
    "        output_key='answer',\n",
    "        memory_key='chat_history',\n",
    "        chat_memory=history,\n",
    "        return_messages=True\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = generate_prompt_with_history()\n",
    "\n",
    "    # The chain\n",
    "    chain = ConversationalRetrievalChain.from_llm(\n",
    "        llm,\n",
    "        retriever=retriever,\n",
    "        memory=memory,\n",
    "        combine_docs_chain_kwargs={\"prompt\": QA_CHAIN_PROMPT},\n",
    "        verbose=True,\n",
    "    )\n",
    "\n",
    "    #QA_CHAIN_PROMPT = PromptTemplate.from_template(template)\n",
    "\n",
    "    output = chain({\"question\": question})\n",
    "\n",
    "    #answer_value = output[\"answer\"]\n",
    "\n",
    "    #print(answer_value)\n",
    "    \n",
    "    return output\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3mGiven the following conversation and a follow up question, rephrase the follow up question to be a standalone question, in its original language.\n",
      "\n",
      "Chat History:\n",
      "\n",
      "Human: What competency and capacity must a third-party certification body have to qualify for accreditation?\n",
      "Assistant: To qualify for accreditation, a third-party certification body must demonstrate that it has the necessary competency and capacity. This includes having adequate resources, such as a sufficient number of employees and agents with relevant knowledge, skills, and experience to effectively examine compliance with food safety requirements, industry standards, and practices. The certification body must also have adequate financial resources for its operations. Additionally, the certification body must show that it has the capability to meet the applicable requirements of the accreditation process, including the ability to conduct audits, issue certifications, and address any deficiencies identified during the auditing process. The certification body must have a written program for monitoring and evaluating the performance of its officers, employees, and other agents involved in auditing and certification activities. It must also have procedures in place to identify and address any deficiencies in its auditing and certification program. Finally, the certification body must have written procedures for establishing, controlling, and retaining records, as well as the capability to meet the reporting, notification, and records requirements of the accreditation process. [Page: 2, 3, 4, 5]\n",
      "Human: 21.21 Changes in systems and newsystems. \n",
      "Assistant: Based on the provided context, there is no specific information about changes in systems or new systems that are required for a third-party certification body to qualify for accreditation. The context mainly focuses on the eligibility criteria and requirements for accreditation, including competency, capacity, resources, quality assurance procedures, and record-keeping procedures. It does not mention any specific changes or new systems that need to be implemented. Therefore, it can be inferred that the existing systems and processes of a third-party certification body should meet the applicable requirements and demonstrate competency and capacity to effectively conduct food safety audits, issue certifications, and comply with industry standards and practices.\n",
      "Human: 21.20 Procedures for notice of Foodand Drug Administration Privacy Act Record Systems? \n",
      "Assistant: The procedures for notice of Food and Drug Administration (FDA) Privacy Act Record Systems are outlined in the provided context. According to the context, the FDA is required to issue a notice of its intention to establish new Privacy Act Record Systems or make changes to existing systems. These notices must be published in the Federal Register for a comment period of at least 30 days prior to implementation. Interested individuals have the opportunity to submit written data, views, or arguments on the proposed new uses or systems.\n",
      "\n",
      "The notice for a Privacy Act Record System should include specific information such as the name and location of the system, categories of individuals and records maintained in the system, authority for the system, routine uses of the records, policies and practices regarding storage and disposal of records, responsible official for the system, notification procedure, record access and contest procedures, sources of records, and any exemptions applicable to the system.\n",
      "\n",
      "These procedures ensure transparency and provide individuals with the opportunity to be informed about the existence and operation of FDA Privacy Act Record Systems and to exercise their rights under the Privacy Act. [Page: 1, 2, 3, 4, 5]\n",
      "Human: What is the Effect of letter of designation? \n",
      "Assistant: The effect of a letter of designation is that it constitutes an agency determination regarding the primary jurisdiction for the premarket review and regulation of a product. The letter specifies the agency component designated to have primary jurisdiction, as well as any consulting agency components. The letter of designation is subject to change only as provided in the regulations. The product jurisdiction officer may change the designated agency component with the written consent of the sponsor or without its consent to protect public health or for other compelling reasons. The sponsor is given notice and an opportunity to submit written objections and may request a meeting with the product jurisdiction officer. The product jurisdiction officer will issue a written determination setting forth the reasons for the proposed change in designated agency component. The letter of designation has legal implications and determines the agency component responsible for the premarket review and regulation of the product. [Page: 2, 3]\n",
      "Human: Are electronic records created under this subpart subject to the electronic records requirements of part 11 of this chapter?\n",
      "Assistant: Yes, the electronic records created under this subpart need to comply with the electronic records requirements of part 11 of this chapter. Part 11 of the chapter establishes the criteria under which electronic records, electronic signatures, and handwritten signatures executed to electronic records are considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures. The regulations in part 11 set forth the standards for the use of electronic records and electronic signatures in place of paper records and handwritten signatures. Therefore, any electronic records created under this subpart must meet the requirements of part 11 to be considered equivalent to paper records and handwritten signatures. [Page: 2, 3]\n",
      "Human: Are the records obtained by FDA under this subpart subject to public disclosure?\n",
      "Assistant: Yes, the records obtained by the FDA under this subpart are subject to public disclosure. According to the provided context, records obtained by the FDA under this subpart are subject to the disclosure requirements under part 20 of this chapter. Part 20 of the chapter outlines the policy and procedures for the disclosure of FDA records to the public. Therefore, the records obtained by the FDA under this subpart must comply with the disclosure requirements specified in part 20 and may be subject to public disclosure. [Page: 1, 2]\n",
      "Human: What are the requirements for submitting abridged analytical reports? \n",
      "Assistant: The requirements for submitting abridged analytical reports are outlined in § 1.1153 of the provided context. A LAAF-accredited laboratory may request permission to submit abridged analytical reports for each major food testing discipline: biological, chemical, and physical. To be granted permission, the laboratory must meet the following conditions:\n",
      "\n",
      "1. The laboratory must not be on suspension or probation for any method within the major food testing discipline.\n",
      "2. The laboratory must have successfully implemented any required corrective action.\n",
      "3. The last five full analytical reports for the major food testing discipline must contain no shortcomings that call into question the validity of the test results or repeated administrative errors.\n",
      "\n",
      "If permission is granted, the laboratory must include specific information in the abridged analytical reports, including all required documentation, quality control results, and any additional information described by ISO/IEC 17025:2017(E) sections 7.8.2.1(a) through (p) and 7.8.3.1(a) through (d).\n",
      "\n",
      "FDA will review all abridged analytical reports submitted and may require additional documentation or a full analytical report in certain circumstances. Failure to submit all required information may result in the related food testing being considered invalid by the FDA. [Page: 1, 2, 3]\n",
      "Human: This guidance provides recommendations to sponsors and/or applicants planning to what? \n",
      "Assistant: This guidance provides recommendations to sponsors and/or applicants planning to develop and submit guidance documents to the Food and Drug Administration (FDA). The guidance outlines the procedures and requirements for the development, issuance, and revision of guidance documents. It provides information on how sponsors and applicants can participate in the development and issuance of guidance documents, including providing input, suggesting areas for guidance document development, and submitting drafts of proposed guidance documents. The guidance also explains the procedures for FDA's review and finalization of guidance documents, as well as the publication and implementation of the final guidance documents. Overall, the guidance aims to ensure that sponsors and applicants understand the process and requirements for developing and submitting guidance documents to the FDA. [Page: 1, 2, 3, 4, 5]\n",
      "Human: what is Bioequivalence? \n",
      "Assistant: The definition of bioequivalence is not provided in the given context.\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods to document bioavailability and bioequivalence include pharmacokinetic studies, other approaches to support bioavailability and bioequivalence, in vitro studies conducted in support of a waiver of in vivo data requirement, in vitro studies conducted in support of demonstrating bioavailability or bioequivalence, and additional information on in vitro approaches. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as AUC, Cmax, and Tmax. Other approaches may include pharmacodynamic studies, studies with clinical benefit endpoints, and other in vitro studies. In vitro studies can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Follow Up Input: METHODS TO DOCUMENT BA AND BE ?\n",
      "Standalone question:\u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new StuffDocumentsChain chain...\u001b[0m\n",
      "\n",
      "\n",
      "\u001b[1m> Entering new LLMChain chain...\u001b[0m\n",
      "Prompt after formatting:\n",
      "\u001b[32;1m\u001b[1;3m\n",
      "    Follow exactly these 5 steps:\n",
      "    1. Read the context below and aggregrate this data\n",
      "    Context :  \n",
      " Draft — Not for Implementation \n",
      " \n",
      "Contains Nonbinding Recommendations \n",
      " \n",
      "487  \n",
      "488 1.  Preapproval Changes \n",
      "489  \n",
      "490 For BA and BE studies, we recommend a singl e-dose, fasting study be performed.  Under \n",
      "491 certain circumstances, multiple-dose BA studies  (see section III.A.5) and/or food effect \n",
      "492 studies may be necessary (See the FDA guidance for industry Food-Effect Bioavailability \n",
      "493 and Fed Bioequivalence). Unconventional dosage forms (buccal, chewable, orally \n",
      "494 disintegrating, and sublingua l dosage forms) should be administered according to \n",
      "495 intended label use/instructi ons.  In addition, a BA study may be needed with the \n",
      "496 unconventional dosage form swallowed intact  to assess the impact of accidental \n",
      "497 swallowing of the intact product. Sampling should adequately capture the T max and C max  \n",
      "498 in addition to total exposure. \n",
      "499  \n",
      "500 We recommend that in vitro dissolution be eval uated for all orally administered products.  \n",
      "501 In vitro dissolution test conditions could be the same or different for unconventional \n",
      "502 compared to conventional dosage forms.  If di fferences in dissolution data exist, they \n",
      "503 should be discussed with the appropriate review division.  \n",
      "504  \n",
      "505 2.  Postapproval Changes \n",
      "506  \n",
      "507 Information on the types of in vitro disso lution and in vivo BE studies needed for \n",
      "508 approved immediate-release drug products when postapproval changes are made is \n",
      "509 provided in an FDA guidance for industry entitled SUPAC-IR: Immediate Release Solid \n",
      "510 Oral Dosage Forms Scale-Up and Postapprov al Changes: Chemistry, Manufacturing, \n",
      "511 and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation . \n",
      "512 We recommend that for postapproval changes, th e in vitro or in vivo comparison be made \n",
      "513 between the post-change and pre-change products. \n",
      "514  \n",
      "515 C.  Modified-Release Products  \n",
      "516  \n",
      "517 Modified-release (MR) products include exte nded-release (controlled-release, sustained-\n",
      "518 release)17 and delayed-release products. \n",
      "519  \n",
      "520 Extended-release (ER) products are dosage forms that are designed to extend or prolong the \n",
      "521 release of active ingredient or  active moiety from the drug pr oduct and may allow a reduction in \n",
      "522 dosing frequency as compared to when the drug is administered in an immediate-release (IR) \n",
      "523 dosage form. These drug products can be developed to reduce fluctuations in plasma  \n",
      "524 concentrations when compared to an IR product. ER products can be capsules, tablets, granules, \n",
      "525 pellets, or suspensions. \n",
      "526  \n",
      "527 Delayed-release (DR) drug products are dosage fo rms that release active ingredient or active \n",
      "528 moiety at a time later than immediately after administration (i.e., these drug products exhibit a \n",
      "529 lag time in quantifiable plasma concentrations).  Typically, coatings (e.g. , enteric coatings) are \n",
      "                                                 \n",
      "17  For the purpose of this guidance, the terms extended , controlled , and  sustained are used interchangeably. \n",
      "13\n",
      "\n",
      " \n",
      "\n",
      " \n",
      " Draft — Not for Implementation \n",
      " \n",
      "Contains Nonbinding Recommendations \n",
      " \n",
      "187  \n",
      "188 III.    METHODS TO DOCUMENT BA AND BE \n",
      "189  \n",
      "190 Under FDA’s regulations, applicants must use the most accurate, sensitive, and reproducible \n",
      "191 method available to demonstrate BA or BE of  a product (21 CFR 320.24(a)).  As noted in 21 \n",
      "192 CFR 320.24, several in vivo and in vitro methods can  be used to measure BA and to establish \n",
      "193 BE. These include, in general order of preferen ce, pharmacokinetic (PK) studies, in vitro tests \n",
      "194 predictive of human in vivo BA (in vitro-in vivo correlation), pharmacodynamic (PD) studies, \n",
      "195 studies with clinical benefit endpoi nts, and other in vitro studies. In addition, where in vivo data \n",
      "196 are appropriate to demonstrate BA, our regulati ons provide guidelines on specific types of in \n",
      "197 vivo BA studies (see 21 CFR 320.25 through 320.29).  This guidance predominantly focuses on \n",
      "198 the use of PK studies to document BA or BE.   \n",
      "199  \n",
      "200 A.  Pharmacokinetic Studies \n",
      "201  \n",
      "202 1.  General Considerations \n",
      "203  \n",
      "204 FDA’s regulations generally defi ne BA and BE in terms of ra te and extent of absorption \n",
      "205 of the active ingredient or moiety to the site of action.9 For in vivo studies, the \n",
      "206 regulations also provide for use of PK measures  in an accessible biological matrix such as \n",
      "207 blood, plasma, and/or serum to indicate rele ase of the drug substance from the drug \n",
      "208 product into the systemic circulation.10  BA and BE frequently rely on PK measures such  \n",
      "209 as AUC to assess extent of  systemic exposure and C max  and T max to assess rate of systemic \n",
      "210 absorption. PK-based comparisons to describe  relative BA or make BE determinations \n",
      "211 are predicated on an understanding that measur ing the active moiety or ingredient at the \n",
      "212 site of action is generally not possible and on an assumption that some relationship exists \n",
      "213 between the efficacy/safety and concentration of the active moiety and/or its important \n",
      "214 metabolite(s) in the systemic circulation.  A typical study is conducted as a crossover \n",
      "215 study. The crossover design reduces variability caused by patient-specific factors, thereby \n",
      "216 increasing the ability to discern differences because of formulation. \n",
      "217  \n",
      "218 2.  Pilot Study  \n",
      "219  \n",
      "220 If the sponsor chooses, a pilo t study in a small number of  subjects can be carried out \n",
      "221 before proceeding with a full-scale BA or BE study. The pilot study can be used to \n",
      "222 validate analytical methodology, assess PK variability, determine samp le size to achieve \n",
      "223 adequate power, optimize sample collection time intervals, and determine the length of  \n",
      "224 the washout period needed between treatme nts.  For example, for conventional \n",
      "225 immediate-release products, careful timing of initial samples may avoid a subsequent \n",
      "226 finding in a full-scale study that the firs t sample collection occurs after the C max. For  \n",
      "227 modified-release products, a pilo t study can help determine the sampling schedule needed \n",
      "                                                 \n",
      "9 21 CFR 320.1(a) and  (e). \n",
      "10 See, e.g., 21  CFR 320.24(b)(1)(i).  If serial measurements  of the drug  or its metabolites in plasma, serum, or blood  \n",
      "cannot be accomplished, t  hen measurement  of urinary  excretion can be used.   \n",
      "6\n",
      "\n",
      " \n",
      "\n",
      " \n",
      " \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      " \n",
      "  \n",
      " \n",
      "  \n",
      "  \n",
      "  \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " TABLE OF CONTENTS \n",
      "I. INTRODUCTION................................................................................................................. 1\n",
      " \n",
      "II. BACKGROUND ................................................................................................................... 2\n",
      " \n",
      "A. G ENERAL  ............................................................................................................................. 3 \n",
      "B. B IOAVAILABILITY  ................................................................................................................ 3 \n",
      "C. B IOEQUIVALENCE  ................................................................................................................ 4 \n",
      "III. METHODS TO DOCUMENT BA AND BE ...................................................................... 6\n",
      " \n",
      "A. P HARMACOKINETIC STUDIES  ............................................................................................... 6 \n",
      "B. O THER APPROACHES TO SUPPORT BA/BE ......................................................................... 10 \n",
      "IV. DOCUMENTING BA AND BE FOR VARIOUS DOSAGE FORMS .......................... 12\n",
      " \n",
      "A. S OLUTIONS AND OTHER SOLUBILIZED DOSAGE FORMS ..................................................... 12 \n",
      "B. I MMEDIATE -RELEASE PRODUCTS ....................................................................................... 12 \n",
      "C. M ODIFIED -RELEASE PRODUCTS ......................................................................................... 13 \n",
      "D. B ATCH SIZE ....................................................................................................................... 16 \n",
      "V.\t ADDITIONAL INFORMATION ON IN VITRO APPROACHES ............................... 16\n",
      " \n",
      "A.\t IN VITRO STUDIES CONDUCTED IN SUPPORT OF A WAIVER OF AN IN VIVO BA OR BE DATA \n",
      "REQUIREMENT  ................................................................................................................... 16 \n",
      "B.\t IN VITRO STUDIES CONDUCTED IN SUPPORT OF DEMONSTRATING BA OR BE .................. 17 \n",
      "VI. SPECIAL TOPICS ............................................................................................................. 20\n",
      " \n",
      "A. A LCOHOLIC BEVERAGE EFFECTS ON MR DRUG PRODUCTS  .............................................. 20 \n",
      "B. E NANTIOMERS VERSUS RACEMATES  .................................................................................. 20 \n",
      "C. D RUG PRODUCTS WITH COMPLEX MIXTURES AS THE ACTIVE INGREDIENTS  .................... 20 \n",
      "D. L ONG-HALF-LIFE DRUGS  .................................................................................................. 21 \n",
      "E. O RALLY ADMINISTERED DRUGS INTENDED FOR LOCAL ACTION ....................................... 21 \n",
      "F. C OMBINATION /COADMINISTERED DRUG PRODUCTS  ......................................................... 21 \n",
      "G. E NDOGENOUS SUBSTANCES  ............................................................................................... 22 \n",
      "H. D RUG PRODUCTS WITH HIGH INTRASUBJECT VARIABILITY  .............................................. 23 \n",
      "APPENDIX A: GENERAL STUDY DE SIGN AND DATA HANDLING ........................... 24\n",
      " \n",
      "\n",
      " \n",
      " \n",
      " \n",
      "  \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " \n",
      " Draft — Not for Implementation \n",
      "Contains Nonbinding Recommendations \n",
      "142 Information on the types of recommended in vi tro dissolution and in vivo BE studies for \n",
      "143 immediate-release and modified-release dr ug products approved as NDAs for specified \n",
      "144 postapproval changes is provided in the following FDA guidances : \n",
      "145 \n",
      "146  SUPAC-IR: Immediate Release Solid Or al Dosage Forms:  Scale-Up and \n",
      "147 Postapproval Changes: Chemistry, Manufacturing, and Control; In Vitro \n",
      "148 Dissolution Testing, and In Vivo  Bioequivalence Documentation \n",
      "149  SUPAC-MR: Modified Release Solid Oral  Dosage Forms:  Scale-Up and \n",
      "150 Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro \n",
      "151 Dissolution Testing, and In Vivo  Bioequivalence Documentation \n",
      "152 \n",
      "153 3. BE Considerations \n",
      "154 \n",
      "155 BE studies are usually conducted using a cross over design.  For such studies, intrasubject \n",
      "156 variability should be considered  when determining the study sample size.  In cases when \n",
      "157 a parallel design is necessary to evaluate BE, consideration shoul d be given to total \n",
      "158 variability, including intersubject variability in stead of just intrasub ject variability.   \n",
      "159 160 A test product might fail to demonstrate bioequivalence because it ha s measures of rate \n",
      "161 and/or extent of absorption compared to th e reference product outside acceptable higher \n",
      "162 or lower limits. For example, when the test product results in a syst emic exposure that is \n",
      "163 significantly higher than that of  the reference product, the concern is the typically limited \n",
      "164 experience from a safety standpoint for higher systemic concentrations.  When the test \n",
      "165 product has a systemic exposure that is signif icantly lower than that of the reference \n",
      "166 product, the concern is potentially a lack of therapeutic efficacy of the test product.  \n",
      "167 When the variability of the test product is gr eater than the reference product, the concern \n",
      "168 relates to both safety and efficacy, because it may suggest that the performance of the test \n",
      "169 product is not comparable to the referen ce product, and the test product may be too \n",
      "170 variable to be c linically useful. \n",
      "171 \n",
      "172 When BE is not demonstrated, the sponsor shoul d demonstrate that the differences in rate \n",
      "173 and extent of absorption do not significantl y affect the safety and efficacy based on \n",
      "174 available dose-response or concen tration-response data.  In th e absence of this evidence, \n",
      "175 failure to demonstrate BE may suggest that the test product should be reformulated, or \n",
      "176 the method of manufacture for the test product should be changed, or additional safety or \n",
      "177 efficacy data may be needed for the test product.  In some cases, conclusions of BE based \n",
      "178 on the peak drug concentration (C\n",
      "max) and area under the plasma concentration time curve \n",
      "179 (AUC) between the test product and the reference product may be insufficient to \n",
      "180 demonstrate that there is no difference in safe ty or efficacy if the systemic concentration­\n",
      "181 time profiles of the test product and the refere nce product are different (e.g., time to reach \n",
      "182 peak drug concentration (T max) is different). For example, differences in the shape of the \n",
      "183 systemic concentration profile between the te st and reference produc ts could imply that \n",
      "184 the test product may not produce the same clin ical response as the reference product.  In \n",
      "185 such cases, additional data analysis (e.g., partial AUCs), exposure-re sponse evaluation, or \n",
      "186 clinical studies may be recommended to evaluate the BE of  the two products. \n",
      "5\n",
      " \n",
      "    2. Answer the question using only this context and the chat history below\n",
      "    3. Answer the question in less than 200 words\n",
      "    4. Please provide the page number of the pages where your answer are based on at the end of your response\n",
      "    5. Please provide the page numbers in the following output format: [Page: 1, 2, 3]\n",
      "    \n",
      "    Chat History: \n",
      "Human: What competency and capacity must a third-party certification body have to qualify for accreditation?\n",
      "Assistant: To qualify for accreditation, a third-party certification body must demonstrate that it has the necessary competency and capacity. This includes having adequate resources, such as a sufficient number of employees and agents with relevant knowledge, skills, and experience to effectively examine compliance with food safety requirements, industry standards, and practices. The certification body must also have adequate financial resources for its operations. Additionally, the certification body must show that it has the capability to meet the applicable requirements of the accreditation process, including the ability to conduct audits, issue certifications, and address any deficiencies identified during the auditing process. The certification body must have a written program for monitoring and evaluating the performance of its officers, employees, and other agents involved in auditing and certification activities. It must also have procedures in place to identify and address any deficiencies in its auditing and certification program. Finally, the certification body must have written procedures for establishing, controlling, and retaining records, as well as the capability to meet the reporting, notification, and records requirements of the accreditation process. [Page: 2, 3, 4, 5]\n",
      "Human: 21.21 Changes in systems and newsystems. \n",
      "Assistant: Based on the provided context, there is no specific information about changes in systems or new systems that are required for a third-party certification body to qualify for accreditation. The context mainly focuses on the eligibility criteria and requirements for accreditation, including competency, capacity, resources, quality assurance procedures, and record-keeping procedures. It does not mention any specific changes or new systems that need to be implemented. Therefore, it can be inferred that the existing systems and processes of a third-party certification body should meet the applicable requirements and demonstrate competency and capacity to effectively conduct food safety audits, issue certifications, and comply with industry standards and practices.\n",
      "Human: 21.20 Procedures for notice of Foodand Drug Administration Privacy Act Record Systems? \n",
      "Assistant: The procedures for notice of Food and Drug Administration (FDA) Privacy Act Record Systems are outlined in the provided context. According to the context, the FDA is required to issue a notice of its intention to establish new Privacy Act Record Systems or make changes to existing systems. These notices must be published in the Federal Register for a comment period of at least 30 days prior to implementation. Interested individuals have the opportunity to submit written data, views, or arguments on the proposed new uses or systems.\n",
      "\n",
      "The notice for a Privacy Act Record System should include specific information such as the name and location of the system, categories of individuals and records maintained in the system, authority for the system, routine uses of the records, policies and practices regarding storage and disposal of records, responsible official for the system, notification procedure, record access and contest procedures, sources of records, and any exemptions applicable to the system.\n",
      "\n",
      "These procedures ensure transparency and provide individuals with the opportunity to be informed about the existence and operation of FDA Privacy Act Record Systems and to exercise their rights under the Privacy Act. [Page: 1, 2, 3, 4, 5]\n",
      "Human: What is the Effect of letter of designation? \n",
      "Assistant: The effect of a letter of designation is that it constitutes an agency determination regarding the primary jurisdiction for the premarket review and regulation of a product. The letter specifies the agency component designated to have primary jurisdiction, as well as any consulting agency components. The letter of designation is subject to change only as provided in the regulations. The product jurisdiction officer may change the designated agency component with the written consent of the sponsor or without its consent to protect public health or for other compelling reasons. The sponsor is given notice and an opportunity to submit written objections and may request a meeting with the product jurisdiction officer. The product jurisdiction officer will issue a written determination setting forth the reasons for the proposed change in designated agency component. The letter of designation has legal implications and determines the agency component responsible for the premarket review and regulation of the product. [Page: 2, 3]\n",
      "Human: Are electronic records created under this subpart subject to the electronic records requirements of part 11 of this chapter?\n",
      "Assistant: Yes, the electronic records created under this subpart need to comply with the electronic records requirements of part 11 of this chapter. Part 11 of the chapter establishes the criteria under which electronic records, electronic signatures, and handwritten signatures executed to electronic records are considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures. The regulations in part 11 set forth the standards for the use of electronic records and electronic signatures in place of paper records and handwritten signatures. Therefore, any electronic records created under this subpart must meet the requirements of part 11 to be considered equivalent to paper records and handwritten signatures. [Page: 2, 3]\n",
      "Human: Are the records obtained by FDA under this subpart subject to public disclosure?\n",
      "Assistant: Yes, the records obtained by the FDA under this subpart are subject to public disclosure. According to the provided context, records obtained by the FDA under this subpart are subject to the disclosure requirements under part 20 of this chapter. Part 20 of the chapter outlines the policy and procedures for the disclosure of FDA records to the public. Therefore, the records obtained by the FDA under this subpart must comply with the disclosure requirements specified in part 20 and may be subject to public disclosure. [Page: 1, 2]\n",
      "Human: What are the requirements for submitting abridged analytical reports? \n",
      "Assistant: The requirements for submitting abridged analytical reports are outlined in § 1.1153 of the provided context. A LAAF-accredited laboratory may request permission to submit abridged analytical reports for each major food testing discipline: biological, chemical, and physical. To be granted permission, the laboratory must meet the following conditions:\n",
      "\n",
      "1. The laboratory must not be on suspension or probation for any method within the major food testing discipline.\n",
      "2. The laboratory must have successfully implemented any required corrective action.\n",
      "3. The last five full analytical reports for the major food testing discipline must contain no shortcomings that call into question the validity of the test results or repeated administrative errors.\n",
      "\n",
      "If permission is granted, the laboratory must include specific information in the abridged analytical reports, including all required documentation, quality control results, and any additional information described by ISO/IEC 17025:2017(E) sections 7.8.2.1(a) through (p) and 7.8.3.1(a) through (d).\n",
      "\n",
      "FDA will review all abridged analytical reports submitted and may require additional documentation or a full analytical report in certain circumstances. Failure to submit all required information may result in the related food testing being considered invalid by the FDA. [Page: 1, 2, 3]\n",
      "Human: This guidance provides recommendations to sponsors and/or applicants planning to what? \n",
      "Assistant: This guidance provides recommendations to sponsors and/or applicants planning to develop and submit guidance documents to the Food and Drug Administration (FDA). The guidance outlines the procedures and requirements for the development, issuance, and revision of guidance documents. It provides information on how sponsors and applicants can participate in the development and issuance of guidance documents, including providing input, suggesting areas for guidance document development, and submitting drafts of proposed guidance documents. The guidance also explains the procedures for FDA's review and finalization of guidance documents, as well as the publication and implementation of the final guidance documents. Overall, the guidance aims to ensure that sponsors and applicants understand the process and requirements for developing and submitting guidance documents to the FDA. [Page: 1, 2, 3, 4, 5]\n",
      "Human: what is Bioequivalence? \n",
      "Assistant: The definition of bioequivalence is not provided in the given context.\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods to document bioavailability and bioequivalence include pharmacokinetic studies, other approaches to support bioavailability and bioequivalence, in vitro studies conducted in support of a waiver of in vivo data requirement, in vitro studies conducted in support of demonstrating bioavailability or bioequivalence, and additional information on in vitro approaches. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as AUC, Cmax, and Tmax. Other approaches may include pharmacodynamic studies, studies with clinical benefit endpoints, and other in vitro studies. In vitro studies can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "Human: METHODS TO DOCUMENT BA AND BE ?\n",
      "Assistant: The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]\n",
      "\n",
      "    User Question: What are the methods used to document bioavailability and bioequivalence?\n",
      "\n",
      "\n",
      "    If you don't have any context and are unsure of the answer, reply that you don't know about this topic.\n",
      "    \u001b[0m\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n",
      "\n",
      "\u001b[1m> Finished chain.\u001b[0m\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'question': 'METHODS TO DOCUMENT BA AND BE ?',\n",
       " 'chat_history': [HumanMessage(content='What competency and capacity must a third-party certification body have to qualify for accreditation?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='To qualify for accreditation, a third-party certification body must demonstrate that it has the necessary competency and capacity. This includes having adequate resources, such as a sufficient number of employees and agents with relevant knowledge, skills, and experience to effectively examine compliance with food safety requirements, industry standards, and practices. The certification body must also have adequate financial resources for its operations. Additionally, the certification body must show that it has the capability to meet the applicable requirements of the accreditation process, including the ability to conduct audits, issue certifications, and address any deficiencies identified during the auditing process. The certification body must have a written program for monitoring and evaluating the performance of its officers, employees, and other agents involved in auditing and certification activities. It must also have procedures in place to identify and address any deficiencies in its auditing and certification program. Finally, the certification body must have written procedures for establishing, controlling, and retaining records, as well as the capability to meet the reporting, notification, and records requirements of the accreditation process. [Page: 2, 3, 4, 5]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='21.21 Changes in systems and newsystems. ', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='Based on the provided context, there is no specific information about changes in systems or new systems that are required for a third-party certification body to qualify for accreditation. The context mainly focuses on the eligibility criteria and requirements for accreditation, including competency, capacity, resources, quality assurance procedures, and record-keeping procedures. It does not mention any specific changes or new systems that need to be implemented. Therefore, it can be inferred that the existing systems and processes of a third-party certification body should meet the applicable requirements and demonstrate competency and capacity to effectively conduct food safety audits, issue certifications, and comply with industry standards and practices.', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='21.20 Procedures for notice of Foodand Drug Administration Privacy Act Record Systems? ', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The procedures for notice of Food and Drug Administration (FDA) Privacy Act Record Systems are outlined in the provided context. According to the context, the FDA is required to issue a notice of its intention to establish new Privacy Act Record Systems or make changes to existing systems. These notices must be published in the Federal Register for a comment period of at least 30 days prior to implementation. Interested individuals have the opportunity to submit written data, views, or arguments on the proposed new uses or systems.\\n\\nThe notice for a Privacy Act Record System should include specific information such as the name and location of the system, categories of individuals and records maintained in the system, authority for the system, routine uses of the records, policies and practices regarding storage and disposal of records, responsible official for the system, notification procedure, record access and contest procedures, sources of records, and any exemptions applicable to the system.\\n\\nThese procedures ensure transparency and provide individuals with the opportunity to be informed about the existence and operation of FDA Privacy Act Record Systems and to exercise their rights under the Privacy Act. [Page: 1, 2, 3, 4, 5]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='What is the Effect of letter of designation? ', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The effect of a letter of designation is that it constitutes an agency determination regarding the primary jurisdiction for the premarket review and regulation of a product. The letter specifies the agency component designated to have primary jurisdiction, as well as any consulting agency components. The letter of designation is subject to change only as provided in the regulations. The product jurisdiction officer may change the designated agency component with the written consent of the sponsor or without its consent to protect public health or for other compelling reasons. The sponsor is given notice and an opportunity to submit written objections and may request a meeting with the product jurisdiction officer. The product jurisdiction officer will issue a written determination setting forth the reasons for the proposed change in designated agency component. The letter of designation has legal implications and determines the agency component responsible for the premarket review and regulation of the product. [Page: 2, 3]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='Are electronic records created under this subpart subject to the electronic records requirements of part 11 of this chapter?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='Yes, the electronic records created under this subpart need to comply with the electronic records requirements of part 11 of this chapter. Part 11 of the chapter establishes the criteria under which electronic records, electronic signatures, and handwritten signatures executed to electronic records are considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures. The regulations in part 11 set forth the standards for the use of electronic records and electronic signatures in place of paper records and handwritten signatures. Therefore, any electronic records created under this subpart must meet the requirements of part 11 to be considered equivalent to paper records and handwritten signatures. [Page: 2, 3]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='Are the records obtained by FDA under this subpart subject to public disclosure?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='Yes, the records obtained by the FDA under this subpart are subject to public disclosure. According to the provided context, records obtained by the FDA under this subpart are subject to the disclosure requirements under part 20 of this chapter. Part 20 of the chapter outlines the policy and procedures for the disclosure of FDA records to the public. Therefore, the records obtained by the FDA under this subpart must comply with the disclosure requirements specified in part 20 and may be subject to public disclosure. [Page: 1, 2]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='What are the requirements for submitting abridged analytical reports? ', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The requirements for submitting abridged analytical reports are outlined in § 1.1153 of the provided context. A LAAF-accredited laboratory may request permission to submit abridged analytical reports for each major food testing discipline: biological, chemical, and physical. To be granted permission, the laboratory must meet the following conditions:\\n\\n1. The laboratory must not be on suspension or probation for any method within the major food testing discipline.\\n2. The laboratory must have successfully implemented any required corrective action.\\n3. The last five full analytical reports for the major food testing discipline must contain no shortcomings that call into question the validity of the test results or repeated administrative errors.\\n\\nIf permission is granted, the laboratory must include specific information in the abridged analytical reports, including all required documentation, quality control results, and any additional information described by ISO/IEC 17025:2017(E) sections 7.8.2.1(a) through (p) and 7.8.3.1(a) through (d).\\n\\nFDA will review all abridged analytical reports submitted and may require additional documentation or a full analytical report in certain circumstances. Failure to submit all required information may result in the related food testing being considered invalid by the FDA. [Page: 1, 2, 3]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='This guidance provides recommendations to sponsors and/or applicants planning to what? ', additional_kwargs={}, example=False),\n",
       "  AIMessage(content=\"This guidance provides recommendations to sponsors and/or applicants planning to develop and submit guidance documents to the Food and Drug Administration (FDA). The guidance outlines the procedures and requirements for the development, issuance, and revision of guidance documents. It provides information on how sponsors and applicants can participate in the development and issuance of guidance documents, including providing input, suggesting areas for guidance document development, and submitting drafts of proposed guidance documents. The guidance also explains the procedures for FDA's review and finalization of guidance documents, as well as the publication and implementation of the final guidance documents. Overall, the guidance aims to ensure that sponsors and applicants understand the process and requirements for developing and submitting guidance documents to the FDA. [Page: 1, 2, 3, 4, 5]\", additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='what is Bioequivalence? ', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The definition of bioequivalence is not provided in the given context.', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='METHODS TO DOCUMENT BA AND BE ?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The methods to document bioavailability and bioequivalence include pharmacokinetic studies, other approaches to support bioavailability and bioequivalence, in vitro studies conducted in support of a waiver of in vivo data requirement, in vitro studies conducted in support of demonstrating bioavailability or bioequivalence, and additional information on in vitro approaches. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as AUC, Cmax, and Tmax. Other approaches may include pharmacodynamic studies, studies with clinical benefit endpoints, and other in vitro studies. In vitro studies can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='METHODS TO DOCUMENT BA AND BE ?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='METHODS TO DOCUMENT BA AND BE ?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='METHODS TO DOCUMENT BA AND BE ?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='METHODS TO DOCUMENT BA AND BE ?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]', additional_kwargs={}, example=False),\n",
       "  HumanMessage(content='METHODS TO DOCUMENT BA AND BE ?', additional_kwargs={}, example=False),\n",
       "  AIMessage(content='The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]', additional_kwargs={}, example=False)],\n",
       " 'answer': 'The methods used to document bioavailability and bioequivalence include pharmacokinetic (PK) studies, in vitro tests predictive of human in vivo bioavailability (in vitro-in vivo correlation), pharmacodynamic (PD) studies, studies with clinical benefit endpoints, and other in vitro studies. Pharmacokinetic studies involve measuring the rate and extent of absorption of the active ingredient or moiety to the site of action using PK measures such as area under the curve (AUC), maximum concentration (Cmax), and time to reach maximum concentration (Tmax). These studies are typically conducted as crossover studies to reduce variability caused by patient-specific factors. In vitro tests can be conducted to assess dissolution and drug release from the dosage form. These methods are used to demonstrate the similarity of a generic drug product to the reference listed drug in terms of bioavailability and bioequivalence. [Page: 6, 17, 20, 21, 24]'}"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question = \"METHODS TO DOCUMENT BA AND BE ?\"\n",
    "\n",
    "llm_pipeline_with_history(question)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'history' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[12], line 11\u001b[0m\n\u001b[0;32m      7\u001b[0m             \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAI: \u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m+\u001b[39m message\u001b[38;5;241m.\u001b[39mcontent)\n\u001b[0;32m      8\u001b[0m         i\u001b[38;5;241m+\u001b[39m\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m\n\u001b[1;32m---> 11\u001b[0m retrieve_chat_history(history)\n",
      "\u001b[1;31mNameError\u001b[0m: name 'history' is not defined"
     ]
    }
   ],
   "source": [
    "def retrieve_chat_history(history):\n",
    "    i = 0\n",
    "    for message in history.messages:\n",
    "        if i % 2 == 0:\n",
    "            print(\"Human: \" + message.content)\n",
    "        else:\n",
    "            print(\"AI: \" + message.content)\n",
    "        i+=1\n",
    "\n",
    "\n",
    "retrieve_chat_history(history)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show langchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip show azure-search-documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "%pip install azure-cosmos"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
